Georgina Maalouf1, Bérangère Arnould2, Olivier Espitia3

  • 1Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Département de Médecine Interne et immunologie Clinique, F-75013, Paris , France , Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire ( CEREMAIA) ; Inflammation-Immunopathology-Biotherapy Department (DMU 3iD) ; CIC Biotherapy ; INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.

PubMed
まとめ

血管炎(LVV)を伴う巨細胞性動脈炎(GCA)の狭窄性病変は、患者の10%未満に影響し、不良な血管転帰と関連している。年齢と椎骨動脈狭窄が合併症の主要なリスク因子である。

関連する概念動画

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
365
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
499
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476